natgillin/translations-raw huggingface dataset:
It is used in adults who are at a low to moderate risk of rejection.
Uporablja se pri odraslih z majhnim do zmernim tveganjem za zavrnitev.
S-LAM is a rare lung disease that causes worsening symptoms such as shortage of breath and occurs mainly in women who are at an age when they can have children.
S-LAM je redka pljučna bolezen, ki povzroča poslabšanje simptomov, kot je pomanjkanje sape, in se pojavlja predvsem pri ženskah v starosti, ko imajo lahko otroke.
Rapamune is available as an oral solution (1 mg/ml) and tablets (0.5, 1 and 2 mg).
Zdravilo Rapamune je na voljo v obliki peroralne raztopine (1 mg/ml) in tablet (0,5 mg, 1 mg in 2 mg).
Other information about Rapamune
Druge informacije o zdravilu Rapamune
To prevent organ rejection, the first dose is usually 6 mg given soon after the transplantation followed by 2 mg once a day.
Za preprečitev zavrnitve organov se prvi odmerek, običajno v jakosti 6 mg, da kmalu po presaditvi, čemur sledi odmerek v jakosti 2 mg enkrat na dan.
As for all medicines, data on the use of Rapamune are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rapamune stalno spremljajo.
The Agency decided that Rapamune's benefits are greater than its risks and it can be authorised for use in the EU.
Zato je zaključila, da so koristi zdravila Rapamune večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Rapamune can then be used for continuing treatment with corticosteroids, but only if ciclosporin treatment can be stopped.
Zdravilo Rapamune se nato lahko uporablja za nadaljevalno zdravljenje s kortikosteroidi, vendar le, če se lahko prekine zdravljenje s ciklosporinom.
What benefits of Rapamune have been shown in studies?
Kakšne koristi zdravila Rapamune so se pokazale v študijah?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rapamune have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rapamune upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Since mTOR is involved in the multiplication of activated T-lymphocytes (white blood cells that are responsible for attacking the transplanted organ), Rapamune reduces the number of these cells, reducing the risk of organ rejection.
Ker mTOR sodeluje pri množenju aktiviranih limfocitov T (belih krvnih celic, ki so odgovorne za napadanje presajenega organa), zdravilo Rapamune zmanjšuje število teh celic, s tem pa tudi tveganje za zavrnitev organa.
The doctor will adjust the dose to achieve appropriate levels of sirolimus in the patient's blood.
Zdravnik bo odmerek prilagodil tako, da bo dosežena ustrezna raven sirolimusa v bolnikovi krvi.
This complex then blocks another protein called ‘mammalian target of rapamycin' (mTOR).
Ta kompleks nato zavira drugo beljakovino, imenovano „tarča rapamicina pri sesalcih“ (mTOR).
Why is Rapamune authorised in the EU?
Zakaj je bilo zdravilo Rapamune odobreno v EU?
Side effects reported with Rapamune are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Rapamune, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
An overview of Rapamune and why it is authorised in the EU
Pregled zdravila Rapamune in zakaj je odobreno v EU
What is Rapamune and what is it used for?
Kaj je zdravilo Rapamune in za kaj se uporablja?
For more information about using Rapamune, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Rapamune glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
In the body, sirolimus attaches to a protein inside cells to make a ‘complex'.
Sirolimus se v telesu veže na beljakovino v celicah in z njo tvori „kompleks“.
It is recommended that Rapamune is used with ciclosporin and corticosteroids (other medicines to prevent organ rejection) for two to three months.
Priporočeno je, da se dva do tri mesece uporablja skupaj s ciklosporinom in kortikosteroidi (drugimi zdravili za preprečevanje zavrnitve organov).
All patients were also treated with ciclosporin and corticosteroids and were at low to moderate risk of rejection.
Vse bolnike so zdravili tudi s ciklosporinom in kortikosteroidi, vsi pa so imeli majhno do srednje veliko tveganje za zavrnitev.
To treat patients with S-LAM, the dose of Rapamune is 2 mg daily and after 10 to 20 days the doctor will adjust the dose to achieve appropriate levels of sirolimus in the patient's blood.
Za zdravljenje bolnikov s S-LAM je odmerek zdravila Rapamune 2 mg na dan, po 10 do 20 dneh pa bo zdravnik odmerek prilagodil tako, da bo dosežena ustrezna raven sirolimusa v bolnikovi krvi.
The active substance in Rapamune, sirolimus, is an immunosuppressant (a medicine that reduces the activity of the immune system).
Učinkovina v zdravilu Rapamune, sirolimus, je imunosupresiv (zdravilo, ki zmanjšuje dejavnost imunskega sistema).
FEV1 improved by an average of 1 ml per month in patients treated with Rapamune compared with a worsening by 12 ml per month in patients receiving placebo.
FEV1 se je pri bolnikih, zdravljenih z zdravilom Rapamune, izboljšal za povprečno 1 ml na mesec, v primerjavi s poslabšanjem za 12 ml na mesec pri bolnikih, zdravljenih s placebom.
Patients allergic to peanut or soya must not take Rapamune oral solution because the solution contains soya oil.
Bolniki, ki so alergični na arašide ali sojo, ne smejo jemati zdravila Rapamune v obliki peroralne raztopine, ker vsebuje sojino olje.
In S-LAM, mTOR is overactive, causing excessive multiplication of cells that cause the disease.
Pri S-LAM je mTOR čezmerno dejaven in povzroča čezmerno razmnoževanje celic, ki povzročajo bolezen.
What are the risks associated with Rapamune?
Kakšna tveganja so povezana z zdravilom Rapamune?
Rapamune was more effective than placebo (a dummy treatment) or azathioprine (another immunosuppressive medicine) in two main studies involving a total of 1,295 patients who were having a kidney transplant.
Zdravilo Rapamune je bilo učinkovitejše od placeba (zdravila brez učinkovine) ali azatioprina (drugega imunosupresivnega zdravila) v dveh glavnih študijah, v kateri je bilo skupno vključenih 1 295 bolnikov, ki so jim presadili ledvico.
Two additional studies looked at Rapamune as continuing treatment for up to 5 years in 765 patients who were able to stop ciclosporin after 2 to 3 months.
V dveh dodatnih študijah so zdravilo Rapamune kot nadaljevalno zdravljenje do pet let opazovali pri skupno 765 bolnikih, ki so se odzvali na prvotno dva- do trimesečno zdravljenje in ki so lahko prenehali jemati ciklosporin.
Rapamune is also used for treating patients with sporadic lymphangioleiomyomatosis (S-LAM) with moderate lung disease or worsening lung function.
Zdravilo Rapamune se uporablja tudi za zdravljenje bolnikov s sporadično limfangioleiomiomatozo (S-LAM) z zmerno pljučno boleznijo ali slabšanjem delovanja pljuč.
In the second study, treatment failed in 30% (68 out of 277) of the patients adding Rapamune, compared with 48% (62 out of 130) of those adding placebo.
V drugi študiji je bilo zdravljenje neuspešno pri 30 % (68 od 277) bolnikov, ki so jim dodajali zdravilo Rapamune, in pri 48 % (62 od 130) bolnikov, ki so jim dodajali placebo.
The European Medicines Agency considered that Rapamune is effective for the prevention of rejection of a transplanted kidney in patients at low to moderate risk of rejection.
Evropska agencija za zdravila je presodila, da je zdravilo Rapamune učinkovito pri preprečevanju zavrnitve presajene ledvice pri bolnikih z majhnim do zmernim tveganjem za zavrnitev organa.
Rapamune contains the active substance sirolimus.
Zdravilo Rapamune vsebuje učinkovino sirolimus.
In the first study, treatment failed in 19% (53 out of 284) of the patients adding Rapamune after 6 months, compared with 32% (52 out of 161) of those adding azathioprine.
V prvi študiji je bilo zdravljenje po šestih mesecih neuspešno pri 19 % (53 od 284) bolnikov, ki so jim dodajali zdravilo Rapamune, in pri 32 % (52 od 161) bolnikov, ki so jim dodajali azatioprin.
The Agency noted that no medicinal product has been approved for the treatment of S-LAM and Rapamune's effect on lung function is considered important.
Ugotovila je, da za zdravljenje S-LAM še ni odobreno nobeno zdravilo in da je učinek zdravila Rapamune na delovanje pljuč pomemben.
Rapamune was effective in helping the new kidney to survive, with an improvement in how well it worked and an improvement in blood pressure when ciclosporin treatment was stopped.
Zdravilo Rapamune je bilo učinkovito in je prispevalo k preživetju in boljšemu delovanju nove ledvice ter izboljšanju krvnega tlaka po prenehanju jemanja ciklosporina.
By blocking mTOR, Rapamune reduces the multiplication of these cells.
Zdravilo Rapamune z zaviranjem mTOR zmanjša razmnoževanje teh celic.
For the full list of side effects and restrictions of Rapamune, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Rapamune glejte navodilo za uporabo.
Rapamune is a medicine used to prevent the body from rejecting a newly transplanted kidney.
Rapamune je zdravilo, ki se uporablja za preprečevanje zavrnitve ledvice po presaditvi.
How is Rapamune used?
Kako se zdravilo Rapamune uporablja?
Rapamune was more effective than placebo in improving lung function in a study involving 81 patients with S-LAM.
Zdravilo Rapamune je bilo v študiji, v katero je bilo vključenih 81 bolnikov s S-LAM, pri izboljšanju delovanja pljuč učinkovitejše od placeba.
How does Rapamune work?
Kako zdravilo Rapamune deluje?
Rapamune treatment should be started by and remain under the guidance of a doctor who is a qualified specialist in transplantation.
Zdravljenje z zdravilom Rapamune sme uvesti in pozneje nadzorovati le usposobljen zdravnik specialist za presaditve.
(Invented) Name Strength
(Izmišljeno) ime
Tesavel is taken at a dose of 100 mg once a day.
Zdravilo Tesavel se jemlje v odmerku 100 mg enkrat na dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Tesavel on 10 January 2008.
Evropska komisija je dovoljenje za promet z zdravilom Tesavel, veljavno po vsej Evropski uniji, odobrila dne 10. januarja 2008.
The full EPAR for Tesavel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tesavel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This authorisation was based on the authorisation granted to Januvia in 2007 (‘informed consent').
Ta odobritev je temeljila na dovoljenju za promet, odobrenemu zdravilu Januvia leta 2007 (uporaba dokumentacije s soglasjem).
Other information about Tesavel
Druge informacije o zdravilu Tesavel
This is a summary of the European public assessment report (EPAR) for Tesavel.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tesavel.
For more information about treatment with Tesavel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Tesavel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefit has Tesavel shown during the studies?
Kakšne koristi je zdravilo Tesavel izkazalo med študijami?
In patients with moderately or severely reduced kidney function the dose of Tesavel should be reduced.
Pri bolnikih z delno ali močno okrnjenim delovanjem ledvic je treba odmerek zdravila Tesavel zmanjšati.
Tesavel must not be used in people who are hypersensitive (allergic) to sitagliptin or any of the other ingredients.
Zdravila Tesavel ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) sitagliptin ali katero koli drugo sestavino zdravila.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tesavel.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Tesavel, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
If Tesavel is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood sugar levels).
Če se zdravilo Tesavel jemlje s sulfonilsečnino ali insulinom, bo morda treba odmerek sulfonilsečnine ali insulina znižati, da se zmanjša tveganje za hipoglikemijo (nizko koncentracijo sladkorja v krvi).
In the studies comparing Tesavel with other medicines, the effectiveness of adding Tesavel to metformin was similar to that of adding glipizide.
V študijah, v katerih so zdravilo Tesavel primerjali z drugimi zdravili, je bila učinkovitost dodajanja zdravila Tesavel metforminu podobna kot pri dodajanju glipizida.
What is the risk associated with Tesavel?
Kakšna tveganja so povezana z zdravilom Tesavel?
The active substance in Tesavel, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Zdravilna učinkovina zdravila Tesavel je sitagliptin, ki je zaviralec dipeptidil peptidaze-4 (DPP-4).
Tesavel is a medicine that contains the active substance sitagliptin.
Tesavel je zdravilo, ki vsebuje zdravilno učinkovino sitagliptin.
Tesavel was studied in nine studies involving almost 6,000 patients with type 2 diabetes whose blood glucose levels were not adequately controlled:
Zdravilo Tesavel je bilo raziskano v devetih glavnih študijah, ki so vključevale skoraj 6 000 bolnikov s sladkorno boleznijo tipa 2, pri katerih ravni glukoze v krvi niso bile zadostno nadzorovane:
• two studies compared Tesavel with other antidiabetes medicines.
• v dveh študijah so zdravilo Tesavel primerjali z drugimi zdravili proti sladkorni bolezni.
Tesavel was more effective than placebo when it was taken alone or in combination with other antidiabetes medicines.
Zdravilo Tesavel je bilo učinkovitejše od placeba, ko so ga bolniki jemali kot samostojno zdravilo ali v kombinaciji z drugimi zdravili proti sladkorni bolezni.
The CHMP decided that Tesavel's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Tesavel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Serious side effects reported with Tesavel include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions).
Med resnimi neželenimi učinki, o katerih so poročali pri uporabi zdravila Tesavel so pankreatitis (vnetje trebušne slinavke) in preobčutljivostne (alergijske) reakcije.
Tesavel is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Zdravilo Tesavel se uporablja za zdravljenje bolnikov s sladkorno boleznijo tipa 2 za izboljšanje nadzora nad ravnjo glukoze (sladkorja) v krvi.
In patients taking Tesavel on its own, HbA1c levels fell from around 8.0% at the start of the studies by 0.48% after 18 weeks and 0.61% after 24 weeks.
Pri bolnikih, ki so jemali samo zdravilo Tesavel so se ravni HbA1c zmanjšale za približno 8 % na začetku študij, za 0,48 % po 18 tednih in za 0,61 % po
For the full list of all side effects reported with Tesavel, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tesavel, glejte navodilo za uporabo.
Why has Tesavel been approved?
Zakaj je bilo zdravilo Tesavel odobreno?
• three additional studies compared Tesavel with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
• v treh dodatnih študijah so zdravilo Tesavel primerjali s placebom, obe zdravili so dodajali drugim zdravilom proti sladkorni bolezni; glimepiridu (drugi vrsti sulfonilsečnine), z metforminom ali brez njega, pri 441 bolnikih ali kombinaciji metformina in rosiglitazona (agonista PPAR-gama) pri 278 bolnikih ali ustaljenemu odmerku insulina, z metforminom ali brez njega, pri 641 bolnikih.
When taken on their own, Tesavel and metformin produced similar reductions in HbA1c levels, but the effectiveness of Tesavel seemed to be slightly lower than that of metformin.
Ob samostojnem jemanju zdravila Tesavel ali metformina so bila znižanja ravni HbA1c podobna, vendar je bilo zdravilo Tesavel malenkost slabše učinkovito kot metformin.
The other study compared Tesavel with metformin, used on their own, in 1,058 patients;
V drugi študiji so zdravilo Tesavel primerjali z metforminom pri 1 058 bolnikih, ki so obe zdravili jemali samostojno;
• in combination with both metformin and a sulphonylurea or a PPAR-gamma agonist, in patients who are not satisfactorily controlled on the two medicines;
• v kombinaciji z metforminom in sulfonilsečnino ali agonistom PPAR-gama pri bolnikih, pri katerih z obema zdraviloma ni vzpostavljen zadosten nadzor;
• on its own, in patients who are not satisfactorily controlled on diet and exercise and in whom metformin (an antidiabetes medicine) is not suitable;
• kot samostojno zdravilo pri bolnikih, katerih bolezen samo z dieto in telesno vadbo ni zadovoljivo nadzorovana in pri katerih metformin (zdravilo za zdravljenje sladkorne bolezni) ni primeren;
HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Tesavel to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Ravni HbA1c so bile po 18 tednih znižane za 1,03 % pri bolnikih, ki so zdravilo Tesavel dodajali metforminu in rosiglitazonu, v primerjavi z znižanjem za 0,31 % pri tistih, ki so kot dodatek prejemali placebo.
Finally, they were reduced by 0.59% in patients adding Tesavel to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo.
Ravni so se znižale za 0,59 % pri bolnikih, ki so zdravilo Tesavel dodajali insulinu (z metforminom ali brez njega) v primerjavi z zmanjšanjem za 0,03 % pri tistih, ki so kot dodatek jemali placebo.
Tesavel or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients;
• v štirih študijah so zdravilo Tesavel primerjali s placebom (zdravilom brez zdravilne učinkovine): zdravilo Tesavel ali placebo so bolniki jemali samostojno v dveh študijah, ki sta vključevali 1 262 bolnikov, kot dodatek metforminu v eni študiji s 701 bolnikom in kot dodatek pioglitazonu (agonistu PPAR-gama) v eni študiji s 353 bolniki;
How does Tesavel work?
Kako zdravilo Tesavel deluje?
In the additional studies, adding Tesavel to glimepiride (with and without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in the patients adding placebo.
V dodatnih študijah je dodajanje zdravila Tesavel glimepiridu (z metforminom ali brez njega) po 24 tednih znižalo ravni HbA1c za 0,45 % v primerjavi s povečanjem za 0,28 % pri bolnikih, pri katerih so dodajali placebo.
What is Tesavel used for?
Za kaj se zdravilo Tesavel uporablja?
How has Tesavel been studied?
Kako je bilo zdravilo Tesavel raziskano?
What is Tesavel?
Kaj je zdravilo Tesavel?
One study compared Tesavel with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients.
V eni študiji so pri 1 172 bolnikih primerjali zdravilo Tesavel z glipizidom (sulfonilsečnino), obe zdravili pa so dodajali metforminu.
When added to pioglitazone, Tesavel reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo.
Če je bilo zdravilo Tesavel dodano pioglitazonu, je po 24 tednih znižalo ravni HbA1c za 0,85 % v primerjavi z znižanjem za 0,15 % pri bolnikih, ki so kot dodatek jemali placebo.
Adding Tesavel to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Če je bilo zdravilo Tesavel dodano metforminu, je po 24 tednih znižalo ravni HbA1c za 0,67 % v primerjavi z znižanjem za 0,02 % pri bolnikih, ki so kot dodatek jemali placebo.
How is Tesavel used?
Kako se zdravilo Tesavel uporablja?
This may limit the damage to nearby healthy tissues.
To lahko omeji poškodbo na bližnja zdrava tkiva.
1 See outcome of safety review carried out in 2018 here.
1 Izid varnostnega pregleda, opravljenega v letu 2018, si lahko ogledate tukaj.
Further information on Xofigo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Xofigo so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It should be used only for patients who have had at least two previous treatments for prostate cancer or who cannot receive other treatments.
Uporabljati se sme samo pri bolnikih, pri katerih sta bili neuspešni vsaj dve predhodni zdravljenji raka prostate ali ki ne morejo prejeti drugih zdravil.
The bones in the body take up radium in the same way as calcium.
Kosti v telesu radij privzemajo enako kot kalcij.
What measures are being taken to ensure the safe and effective use of Xofigo?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xofigo?
The European Medicines Agency decided that Xofigo's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Xofigo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Xofigo received a marketing authorisation valid throughout the EU on 13 November 2013.
Za zdravilo Xofigo je bilo 13. novembra 2013 izdano dovoljenje za promet, veljavno po vsej EU.
Other information about Xofigo
Druge informacije o zdravilu Xofigo
Patients given Xofigo lived on average for 14.9 months, compared with 11.3 months for those given placebo.
Bolniki, ki so prejemali Xofigo, so preživeli 14,9 meseca, tisti, ki so prejemali placebo, pa 11,3 meseca.
Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection.
Bolniki so v enomesečnih razmikih prejeli do šest injekcij, spremljali pa so jih do tri leta od prvega injiciranja.
Injections are repeated every 4 weeks for a total of 6 injections.
Injiciranje je treba ponavljati vsake štiri tedne, bolnik pa skupno prejme šest injekcij.
As for all medicines, data on the use of Xofigo are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xofigo stalno spremljajo.
The medicine is slowly injected into a vein usually for up to one minute.
Zdravilo se počasi, običajno do največ eno minuto, injicira v veno.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xofigo have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xofigo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Xofigo must not be used with the medicine abiraterone acetate and the corticosteroids prednisone or prednisolone.
Zdravilo Xofigo se ne sme uporabljati z abirateron acetatom ali kortikosteroidom prednizonom ali prednizolonom.
The radioactive radium builds up in bone tissues where the cancer has spread, and the alpha particles destroy surrounding cancer cells and help to control the associated symptoms.
Radioaktivni radij se kopiči v kostnih tkivih, v katere se je razširil rak, delci alfa pa uničujejo okoliške rakave celice in pomagajo nadzorovati simptome bolezni.